文献速递临床试验与 GCP基础与转化研究新药、器械与细胞基因治疗研发

益生菌治疗成人冲动性研究方案:多中心双盲随机安慰剂对照试验

Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial.
PubMed 文献 · Trials · 2020-02-11

本研究为多中心、双盲、随机、安慰剂对照试验,计划筛查180名18-65岁伴有高冲动行为且诊断为注意缺陷/多动障碍和/或边缘型人格障碍的成人,比较合生元配方与安慰剂的疗效。主要结局为安慰剂对照阶段结束时的应答率,应答定义为临床总体印象改善量表评分为1或2分且情感反应指数总分较基线降低至少30%。

要点

  • 首项评估合生元补充对减少冲动和强迫行为效果的随机对照试验。
  • 主要结局为治疗结束时CGI-I评分1或2分且情感反应指数降低≥30%的应答率。
  • 将评估干预对遗传学、微生物群及多种血液生物标志物的影响。

核心结论

  • 合生元补充可能成为减少高冲动和/或强迫行为成人症状的有效治疗,但疗效尚待本试验验证。

研究设计与样本

  • 前瞻性、多中心、双盲、随机、安慰剂对照试验,设合生元配方组与安慰剂组两个臂。
  • 计划在三个研究中心筛查180名18-65岁伴有高冲动行为且诊断为ADHD和/或边缘型人格障碍的参与者。

主要发现

  • 原文未报告试验结果,仅描述研究方案。

关键数值与推荐

  • 主要结局为安慰剂对照阶段结束时的应答率,应答定义为CGI-I评分为1或2分(非常改善或显著改善)且情感反应指数总分较基线降低至少30%。
  • 次要结局包括一般精神病理学、ADHD症状、神经认知功能、躯体参数、体力活动、营养摄入和健康相关生活质量的变化。
  • 还将评估干预对遗传学、微生物群和多种血液生物标志物的影响,并在1周随访时探索胃肠道症状和躯体主诉。

临床怎么用

  • 若试验证实减少冲动和强迫行为的效果,可能为这类患者提供新的成本效益治疗选择。
  • 本试验有助于阐明肠道微生物组与大脑之间交互作用的机制。

局限性

  • 原文未报告试验结果,无法评估疗效和安全性。
  • 研究方案尚未提供样本量计算依据、随机化方法、盲法实施细节等局限性相关信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Impulsivity and compulsivity are related to emotional and social maladjustment and often underlie psychiatric disorders. Recently, alterations in microbiota composition have been shown to have implications for brain development and social behavior via the microbiota-gut-brain axis. However, the exact mechanisms are not fully identified. Recent evidence suggests the modulatory effect of synbiotics on gut microbiota and the contribution of these agents in ameliorating symptoms of many psychiatric diseases. To date, no randomized controlled trial has been performed to establish the feasibility and efficacy of this intervention targeting the reduction of impulsivity and compulsivity. We hypothesize that supplementation with synbiotics may be an effective treatment in adults with high levels of impulsivity and/or compulsivity. METHODS/DESIGN: This is a prospective, multicenter, double-blind, randomized controlled trial with two arms: treatment with a synbiotic formula versus placebo treatment. The primary outcome is the response rate at the end of the placebo-controlled phase (response defined as a Clinical Global Impression-Improvement Scale score of 1 or 2 = very much improved or much improved, plus a reduction in the Affective Reactivity Index total score of at least 30% compared with baseline). A total of 180 participants with highly impulsive behavior and a diagnosis of attention deficit/hyperactivity disorder (ADHD) and/or borderline personality disorder, aged 18-65 years old, will be screened at three study centers. Secondary outcome measures, including changes in general psychopathology, ADHD symptoms, neurocognitive function, somatic parameters, physical activity, nutritional intake, and health-related quality of life, will be explored at assessments before, during, and at the end of the intervention. The effect of the intervention on genetics, microbiota, and several blood biomarkers will also be assessed. Gastrointestinal symptoms and somatic complaints will additionally be explored at 1-week follow-up. DISCUSSION: This is the first randomized controlled trial to determine the effects of supplementation with synbiotics on reducing impulsive and compulsive behavior. This clinical trial can contribute to explaining the mechanisms involved in the crosstalk between the intestinal microbiome and the brain. If effects can be established by reducing impulsive and compulsive behavior, new cost-effective treatments might become available to these patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03495375. Registered on 26 February 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Arteaga-Henríquez G, Rosales-Ortiz SK, Arias-Vásquez A, et al. Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial. Trials. 2020. PMID: 32046750. doi:10.1186/s13063-019-4040-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。